Holen Sie sich die Stockscreener-App
30.02
0.00%
0.00
Handel nachbörslich:
29.90
-0.12
-0.40%
Schlusskurs vom Vortag:
$30.02
Offen:
$30.06
24-Stunden-Volumen:
547.12K
Relative Volume:
2.71
Marktkapitalisierung:
$1.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-198.12M
KGV:
-8.9104
EPS:
-3.3691
Netto-Cashflow:
$-159.74M
1W Leistung:
+6.38%
1M Leistung:
+5.11%
6M Leistung:
+38.21%
1J Leistung:
+60.88%
1-Tages-Spanne:
$29.51
$30.61
1-Wochen-Bereich:
$28.50
$31.14
52-Wochen-Spanne:
$14.59
$31.14
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
30.02 | 1.96B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris Insider Sold Shares Worth $427,419, According to a Recent SEC Filing - marketscreener.com
Pharvaris (PHVS) CMO exercises $2.59 options, sells 14,166 shares under 10b5-1 plan - Stock Titan
Pharvaris N.v. Insider Sold Shares Worth $996,545, According to a Recent SEC Filing - Moomoo
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Should New Deucrictibant Data on Dual HAE Use Require Action From Pharvaris (PHVS) Investors? - Sahm
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next - AOL.com
Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Anne Lesage Sells 3,700 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock - MarketBeat
Johannes Gerardus Chri Schikan Sells 29,070 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 21,700 Shares of Stock - MarketBeat
Director at Pharvaris (NASDAQ: PHVS) trims stake via preset 10b5-1 sales - Stock Titan
Pharvaris (PHVS) exec Lesage sells 48K shares, exercises options - Stock Titan
Planned 18,733-share sale by Pharvaris (PHVS) chief medical officer - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Down 6%Should You Sell? - MarketBeat
Pharvaris moves closer to new preventive treatment for rare swelling disorder - MSN
Pharvaris Director Schikan Sells $213K in Shares Under Rule 10b5-1 PlanNews and Statistics - IndexBox
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighTime to Buy? - MarketBeat
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next - The Motley Fool
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Chiesi snags on-demand HAE drug in $1.9B Kalvista buy - BioWorld News
Pharvaris N.V. (NASDAQ:PHVS) Short Interest Update - MarketBeat
PHVS Pharvaris N.V. shares climb nearly 5 percent despite fourth quarter 2025 earnings missing analyst estimates.GDR - Newser
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells 7,000 Shares of Stock - MarketBeat
Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 7,500 Shares of Stock - MarketBeat
[Form 4] Pharvaris N.V. Insider Trading Activity - Stock Titan
Pharvaris (NASDAQ:PHVS) Insider Sells $210,380.05 in Stock - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap Down Following Insider Selling - MarketBeat
Pharvaris (PHVS) CMO trades shares in scheduled 10b5-1 option exercise - Stock Titan
Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing - marketscreener.com
Pharvaris (NASDAQ:PHVS) Sets New 1-Year HighHere's Why - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Technical Analysis | Q4 2025: Below ExpectationsRating Upgrade - Xã Thanh Hà
[144] Pharvaris N.V. SEC Filing - Stock Titan
Is Evidence Backing Dual Deucrictibant Use Altering The Investment Case For Pharvaris (PHVS)? - Sahm
Pharvaris presents safety data on combined deucrictibant use By Investing.com - Investing.com Australia
Pharvaris N.V. (PHVS) CMO reports 226-share tax withholding event - Stock Titan
Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares but retains large stake - Stock Titan
Pharvaris says one drug may cover both HAE prevention and breakthrough attacks - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighShould You Buy? - MarketBeat
Peng Lu Net Worth (2026) - GuruFocus
Anne Lesage Net Worth (2026) - GuruFocus
Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 ConferenceSlideshow (NASDAQ:PHVS) 2026-04-17 - Seeking Alpha
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a 62.93% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Affiliate files Rule 144 to sell 2,292 shares (PHVS) — prior 23,333-share 10b5-1 sale - Stock Titan
PHVS Maintained at Buy by Citigroup, April 2026 - Meyka
Pharvaris (PHVS) officer has shares withheld to cover RSU tax obligations - Stock Titan
Anna Nijdam Net Worth (2026) - GuruFocus
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):